Neuroprotection in Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is progressive, devastating syndrome that affects both upper and motor neurons. It results in limbs and facial motor weakness, atrophy, spasticity, and death due to respiratory paralysis occurs in 3–5 years. It is referred to as motor neuron disease in UK and some other European countries and as Charcot’s disease in France. It is also referred to as Lou Gehrig’s disease in the US.
- Geevasinga N, Menon P, Ng K, et al. Riluzole exerts transient modulating effects on cortical and axonal hyperexcitability in ALS. Amyotroph Lateral Scler Frontotemporal Degener 2016:1–9.Google Scholar
- Jain KK. Glatiramer acetate. In, Roos RP (ed) MedLink Neurology. Medlink Publishing Corporation, San Diego, California, 2019.Google Scholar
- Jain KK. Riluzole. In, Roos RP (ed) MedLink Neurology. Medlink Publishing Corporation, San Diego, California, 2019a.Google Scholar
- Kindy M, Lupinacci P, Chau R, et al. A Phase 2A randomized, double-blind, placebo-controlled pilot trial of GM604 in patients with Amyotrophic Lateral Sclerosis (ALS Protocol GALS-001) and a single compassionate patient treatment (Protocol GALS-C). F1000Research 2017; 6:230 ( https://doi.org/10.12688/f1000research.10519.1)CrossRefGoogle Scholar
- Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2012;3:CD001447.Google Scholar